65 related articles for article (PubMed ID: 35930753)
21. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in
Pillai R; LeBoeuf SE; Hao Y; New C; Blum JLE; Rashidfarrokhi A; Huang SM; Bahamon C; Wu WL; Karadal-Ferrena B; Herrera A; Ivanova E; Cross M; Bossowski JP; Ding H; Hayashi M; Rajalingam S; Karakousi T; Sayin VI; Khanna KM; Wong KK; Wild R; Tsirigos A; Poirier JT; Rudin CM; Davidson SM; Koralov SB; Papagiannakopoulos T
Sci Adv; 2024 Mar; 10(13):eadm9859. PubMed ID: 38536921
[TBL] [Abstract][Full Text] [Related]
22. Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment.
Fan Y; Xue H; Li Z; Huo M; Gao H; Guan X
Front Pharmacol; 2024; 15():1345522. PubMed ID: 38510646
[TBL] [Abstract][Full Text] [Related]
23. A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle.
Wang B; Pei J; Xu S; Liu J; Yu J
J Exp Clin Cancer Res; 2024 Mar; 43(1):74. PubMed ID: 38459595
[TBL] [Abstract][Full Text] [Related]
24. Targeting glutamine metabolism exhibits anti-tumor effects in thyroid cancer.
Zhang GQ; Xi C; Ju NT; Shen CT; Qiu ZL; Song HJ; Luo QY
J Endocrinol Invest; 2024 Feb; ():. PubMed ID: 38386265
[TBL] [Abstract][Full Text] [Related]
25. Glutamine addiction in tumor cell: oncogene regulation and clinical treatment.
Li X; Peng X; Li Y; Wei S; He G; Liu J; Li X; Yang S; Li D; Lin W; Fang J; Yang L; Li H
Cell Commun Signal; 2024 Jan; 22(1):12. PubMed ID: 38172980
[TBL] [Abstract][Full Text] [Related]
26. Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.
Moon D; Hauck JS; Jiang X; Quang H; Xu L; Zhang F; Gao X; Wild R; Everitt JI; Macias E; He Y; Huang J
Prostate; 2024 Mar; 84(4):349-357. PubMed ID: 38084059
[TBL] [Abstract][Full Text] [Related]
27. Discovery of
Novotná K; Tenora L; Prchalová E; Paule J; Alt J; Veeravalli V; Lam J; Wu Y; Šnajdr I; Gori S; Mettu VS; Tsukamoto T; Majer P; Slusher BS; Rais R
J Med Chem; 2023 Nov; 66(22):15493-15510. PubMed ID: 37949450
[TBL] [Abstract][Full Text] [Related]
28. Metabolic reprogramming, autophagy, and ferroptosis: Novel arsenals to overcome immunotherapy resistance in gastrointestinal cancer.
Wang X; Zhou L; Wang H; Chen W; Jiang L; Ming G; Wang J
Cancer Med; 2023 Nov; 12(21):20573-20589. PubMed ID: 37860928
[TBL] [Abstract][Full Text] [Related]
29. Metabolic control of cancer metastasis: role of amino acids at secondary organ sites.
Karno B; Edwards DN; Chen J
Oncogene; 2023 Nov; 42(47):3447-3456. PubMed ID: 37848626
[TBL] [Abstract][Full Text] [Related]
30. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism.
Encarnación-Rosado J; Sohn ASW; Biancur DE; Lin EY; Osorio-Vasquez V; Rodrick T; González-Baerga D; Zhao E; Yokoyama Y; Simeone DM; Jones DR; Parker SJ; Wild R; Kimmelman AC
Nat Cancer; 2024 Jan; 5(1):85-99. PubMed ID: 37814010
[TBL] [Abstract][Full Text] [Related]
31. Tumor microenvironmental nutrients, cellular responses, and cancer.
Lobel GP; Jiang Y; Simon MC
Cell Chem Biol; 2023 Sep; 30(9):1015-1032. PubMed ID: 37703882
[TBL] [Abstract][Full Text] [Related]
32. Small molecule inhibitors for cancer metabolism: promising prospects to be explored.
Liu D; Wang H; Li X; Liu J; Zhang Y; Hu J
J Cancer Res Clin Oncol; 2023 Aug; 149(10):8051-8076. PubMed ID: 37002510
[TBL] [Abstract][Full Text] [Related]
33. Overview of Cancer Metabolism and Signaling Transduction.
Chae HS; Hong ST
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613455
[TBL] [Abstract][Full Text] [Related]
34. Glutamine metabolism and radiosensitivity: Beyond the Warburg effect.
Alden RS; Kamran MZ; Bashjawish BA; Simone BA
Front Oncol; 2022; 12():1070514. PubMed ID: 36465373
[TBL] [Abstract][Full Text] [Related]
35. Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer.
Choi SYC; Ribeiro CF; Wang Y; Loda M; Plymate SR; Uo T
Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358940
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy.
Nair R; Gupta P; Shanmugam M
Front Oncol; 2022; 12():1000106. PubMed ID: 36185202
[TBL] [Abstract][Full Text] [Related]
37. Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems.
Yokoyama Y; Estok TM; Wild R
Mol Cancer Ther; 2022 Oct; 21(10):1561-1572. PubMed ID: 35930753
[TBL] [Abstract][Full Text] [Related]
38. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R; Lemberg KM; Tenora L; Arwood ML; Pal A; Alt J; Wu Y; Lam J; Aguilar JMH; Zhao L; Peters DE; Tallon C; Pandey R; Thomas AG; Dash RP; Seiwert T; Majer P; Leone RD; Powell JD; Slusher BS
Sci Adv; 2022 Nov; 8(46):eabq5925. PubMed ID: 36383674
[TBL] [Abstract][Full Text] [Related]
39. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
